Business Wire

CA-LINKSYS

13.9.2023 22:48:28 CEST | Business Wire | Press release

Share
Linksys Announces the Next Step in Home and Small Office Connectivity

Linksys®, an iconic Home and Small Office connectivity company, announces in a statement of direction its new Cognitive Experience technology. Cognitive Experience brings a whole new level of intelligence to networking with cutting-edge technological features specially designed to enhance and improve the user experience.

In the technology space, the word “cognitive” refers to “thinking technologies” that can deterministically – either by user selection or automation – solve problems. Developed based on user input and feedback, Cognitive Experience focuses on saving time and effort by automating the process for reporting technical issues to customer support agents.

“Currently 50% of our Support calls are dead air, nobody talking, as our Guardians review the logs and network information while the customer is on the phone,” said Lucas Peterson, Head of Product Support at Linksys. “With Linksys Cognitive Experience, we get all the information we need sent upfront through automation so that our Guardians can review and diagnose before they call the customer. This coupled with our ability to temporarily co-administer the network — with the customer’s permission, of course — will enable us to solve problems in lightning-fast time.”

Cognitive Experience allows a Linksys customer service agent to analyze your technical issue remotely, so that when they contact the user, they have all the information necessary to address the problem. Customer service agents can then administer tech support remotely through your network. You’re able to grant or rescind access to the network at any time. This allows customer service agents to effectively tackle any issues in lightning-fast time.

In Phase 1 of its implementation, Cognitive Experience features will focus on the following:

  • If you experience a problem with your WiFi network, Cognitive Experience is able to run a test on your network
  • Open a trouble-ticket from the Linksys App and get a call from Linksys customer service agents
  • An agent will review the report and can easily access your network, with your permission, to address the problem
  • Cognitive Experience will run a health check on your network to locate any additional potential issues

Phase 1 of Linksys Cognitive Experience is set to be completed by the end of this calendar year. Cognitive Experience will make its debut with products in the Linksys Designer Series through the end of the year. Starting in 2024, Cognitive Experience will be available in other Linksys products.

Phase 2 of Linksys Cognitive Experience is currently under development and includes new “intelligent notifications” that humanize or personalize the insights derived from your network, delivered in a meaningful way.

Examples of intelligent notifications include:

  • When a network’s WAN goes down, we verify the Home Network is operating and then send a WAN Down notification
  • When a network’s WAN comes back up, we verify it and retest the Home Network and send WAN Up and Home Network Up notifications
  • Users can select certain devices to be notified when they leave and rejoin the network

Designer Series offerings that include Cognitive Experience are:

  • Velop Pro 6E – currently available in the US at Amazon, Best Buy and Linksys.com
  • Velop Pro 7 – expected in September/October, now available for pre order at Amazon and Best Buy
  • Velop Micro Router 6 – expected in October/November
  • Velop Micro Mesh 6 – expected in October/November

About Linksys

At Linksys, we engineer simplicity so that you never experience complexity. Linksys is an iconic brand celebrating its 35th year of innovation in Home and Small Office connectivity. With many industry firsts to its credit, Linksys delivers simple, fast, reliable, and affordable products for the Home and Small Office where there is “no IT.”

© 2023 Linksys Holdings, Inc. and/or its affiliates. All rights reserved.

Linksys and many product names and logos are trademarks of Linksys Holdings Inc. and/or its affiliates. Third-party trademarks mentioned are the property of their respective owners.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230913706425/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Three Chugai Researchers Behind the Discovery of Hemlibra for Hemophilia A Receive Prestigious U.S. Lasker Award, One of the World’s Most Respected Scientific Honors9.9.2026 15:45:00 CEST | Press release

- Recognized for the invention of a bispecific antibody that transformed treatment paradigm through an unconventional approach – Recognized for realizing a novel drug discovery concept in which a bispecific antibody replaces the function of coagulation Factor VIII, which is deficient in hemophilia A. Provided improved convenience through prolonged activity and subcutaneous administration, and provided a treatment option regardless of factor VIII inhibitors, thereby helping address unmet medical needs in hemophilia A. First time since the establishment of the Lasker Foundation in 1945 that three Japanese researchers have received the award simultaneously. Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) today announced that Dr. Kunihiro Hattori (former Senior Fellow of Chugai), Dr. Takehisa Kitazawa (Deputy Head of Research Division, Chugai), and Dr. Tomoyuki Igawa (Head of Research Division, Chugai), who led the creation of Hemlibra (emicizumab), a treatment for hemophilia A, have been aw

AMCS Appoints Richard Humphrey as Chief Product and Technology Officer9.9.2026 15:00:00 CEST | Press release

Industrial software executive to lead global product strategy and accelerate AI innovation AMCS, a leading technology provider for the waste and recycling industry, today announced the appointment of Richard Humphrey as Chief Product and Technology Officer. Based in Boston, Humphrey will lead the company’s global product organisation. Humphrey brings more than 25 years of experience developing software for construction and other complex industrial environments. He joins AMCS as the company deepens its focus on waste and recycling and expands the role of AI across its platform. Most recently, Humphrey served as Chief Product and Technology Officer at Contruent, where he led product strategy for a construction cost-management platform used on major capital programmes. He previously held vice president roles at Bentley Systems and B2W Software. Earlier in his career, he spent more than a decade at Autodesk, where he led its Civil Design and Construction software business as Senior Directo

BBH Launches a New Technology Business, Braid, Solving for Intelligent Data Transformation9.9.2026 14:45:00 CEST | Press release

Braid’s agentic AI platform is purpose-built for financial services firms who need to transform, connect, and manage their data with confidence Brown Brothers Harriman (BBH) today announced the launch of a new technology affiliate, Braid LLC, focused on solving enterprise data transformation for financial services. Braid offers an AI-native data transformation platform that gives firms a scale solution to transform, connect, and manage their data with confidence. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260909294398/en/ Braid empowers teams to build, automate, and oversee reliable production-grade data transformations in a fraction of the time typically required today. Instead of requiring engineers to build data automations, Braid allows business users to describe their needs in natural language that AI agents use to build intelligent data transformations that are transparent and fully auditable. Braid’s enterprise-gr

LTM Collaborates with IBM and Red Hat on Lightwell to Advance AI-Driven Open-Source Software Remediation9.9.2026 14:30:00 CEST | Press release

Strengthens software supply chains by helping enterprises transform vulnerability discovery into scalable remediation outcomes LTM, the Business Creativity partner to the world's largest enterprises, today announced that it has collaborated with IBM and Red Hat on Lightwell to help enterprises safeguard the open-source software supply chain through AI-driven vulnerability remediation. As AI accelerates the discovery of software vulnerabilities, organizations must move beyond detection-focused approaches and adopt enterprise-scale remediation strategies that enable rapid risk mitigation without disrupting business-critical applications. Lightwell’s approach of delivering validated fixes for production environments aligns with LTM's aim of helping customers build secure, resilient, and operationally efficient software supply chains. By combining AI-powered remediation capabilities with enterprise-grade validation and deployment support, Lightwell aims to help organizations address securi

New England Journal of Medicine Publishes Data from Phase 3 Studies Demonstrating Oveporexton (ORZEYFUL) Improved the Full Range of Narcolepsy Type 1 Symptoms and Quality of Life9.9.2026 14:24:00 CEST | Press release

Data Demonstrated Significant and Clinically Meaningful Improvements with the Potential to Redefine Narcolepsy Type 1 (NT1) Care Beyond Individual Symptoms Oveporexton was Generally Well-Tolerated with Safety Profile Consistent with Previous Clinical Studies Oveporexton is the First and Only Approved Orexin Agonist Designed to Treat the Underlying Cause of NT1 and is Now Approved in the U.S., China and Japan, with Additional Regulatory Submissions Underway Takeda (TSE:4502/NYSE:TAK) announced that the New England Journal of Medicine published results from two Phase 3 studies evaluating oveporexton (ORZEYFUL), an oral orexin receptor 2 (OX2R) agonist, in people with narcolepsy type 1 (NT1).1 Oveporexton is the first and only medicine to treat the underlying cause of NT1. "People living with narcolepsy type 1 face persistent symptoms across the day and night, which can impact many aspects of daily life,” said Emmanuel Mignot, M.D., Ph.D., principal investigator for the FirstLight (TAK-86

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye